Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.63 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17756704 | 1.00 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL17756696 | 0.98 | CYP4F2 (0.60) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL17756706 | 0.97 | CYP4F2 (0.58) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL17746745 | 0.93 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL17746731 | 0.93 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL20371022 | 0.92 | CYP4F2 (0.69) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL3040974 | 0.92 | CYP4F2 (0.68) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL17746737 | 0.90 | CYP4F2 (0.66) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL22016457 | 0.89 | CYP4F2 (0.65) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL6253618 | 0.87 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170158601-A9 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2017-06-08 | — | — | US | disclosed |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | CYP4F2 129/4885CYP4A11 250/4885HTT 3934/4885 |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | BCKDK, DGKI, DDC | CYP4F2 87/4885CYP4A11 155/4885HTT 3221/4885 |
| US-20170158601-A9 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | BCKDK, DGKI, DDC | CYP4F2 87/4885CYP4A11 155/4885HTT 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.